KRAS and non-small cell lung carcinoma: SHP2 inhibition alone had very little or no effect on proliferation in non-small-cell lung cancer (NSCLCs) cell lines; however, a combination of SHP2 and MEK inhibitors showed marked synergy in K-RAS-mutant NSCLC cells and in animal models [42, 43].